Mainstay Capital Management LLC ADV Sells 4,054 Shares of McKesson Corporation $MCK

Mainstay Capital Management LLC ADV cut its holdings in McKesson Corporation (NYSE:MCK) by 49.2% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 4,188 shares of the company’s stock after selling 4,054 shares during the quarter. McKesson makes up 0.3% of Mainstay Capital Management LLC ADV’s portfolio, making the stock its 24th largest position. Mainstay Capital Management LLC ADV’s holdings in McKesson were worth $3,235,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Obsidian Personal Planning Solutions LLC grew its holdings in McKesson by 2.9% during the 3rd quarter. Obsidian Personal Planning Solutions LLC now owns 426 shares of the company’s stock worth $346,000 after acquiring an additional 12 shares during the last quarter. IAM Advisory LLC raised its stake in shares of McKesson by 0.3% in the third quarter. IAM Advisory LLC now owns 3,908 shares of the company’s stock worth $3,019,000 after acquiring an additional 13 shares during the last quarter. PDS Planning Inc lifted its position in shares of McKesson by 1.1% during the third quarter. PDS Planning Inc now owns 1,209 shares of the company’s stock worth $934,000 after purchasing an additional 13 shares in the last quarter. Berkshire Asset Management LLC PA lifted its position in shares of McKesson by 4.6% during the third quarter. Berkshire Asset Management LLC PA now owns 294 shares of the company’s stock worth $227,000 after purchasing an additional 13 shares in the last quarter. Finally, Goldstein Advisors LLC grew its stake in shares of McKesson by 4.4% during the third quarter. Goldstein Advisors LLC now owns 334 shares of the company’s stock valued at $258,000 after purchasing an additional 14 shares during the last quarter. Institutional investors and hedge funds own 85.07% of the company’s stock.

McKesson Stock Performance

Shares of McKesson stock opened at $920.48 on Thursday. The firm has a fifty day moving average of $900.55 and a two-hundred day moving average of $830.63. The stock has a market capitalization of $112.75 billion, a price-to-earnings ratio of 26.47, a PEG ratio of 1.52 and a beta of 0.38. McKesson Corporation has a 52 week low of $637.00 and a 52 week high of $999.00.

McKesson (NYSE:MCK) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The business had revenue of $106.16 billion for the quarter, compared to analyst estimates of $105.98 billion. During the same period last year, the company earned $8.03 EPS. The firm’s revenue was up 11.4% on a year-over-year basis. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, research analysts forecast that McKesson Corporation will post 32.77 EPS for the current fiscal year.

McKesson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be issued a dividend of $0.82 per share. The ex-dividend date is Monday, March 2nd. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. McKesson’s dividend payout ratio (DPR) is 9.43%.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on MCK. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of McKesson in a report on Wednesday, December 10th. Evercore restated an “outperform” rating on shares of McKesson in a research report on Thursday, March 5th. Barclays raised their price target on McKesson from $960.00 to $1,050.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Leerink Partners reissued an “outperform” rating and set a $1,085.00 price objective on shares of McKesson in a report on Thursday, March 5th. Finally, Raymond James Financial set a $970.00 target price on shares of McKesson in a research report on Thursday, March 5th. Thirteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $960.93.

Insider Activity at McKesson

In other news, EVP Thomas L. Rodgers sold 276 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $816.18, for a total transaction of $225,265.68. Following the completion of the transaction, the executive vice president directly owned 2,268 shares in the company, valued at approximately $1,851,096.24. The trade was a 10.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Leann B. Smith sold 190 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $945.00, for a total value of $179,550.00. Following the completion of the sale, the executive vice president directly owned 2,989 shares of the company’s stock, valued at approximately $2,824,605. This trade represents a 5.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 3,868 shares of company stock worth $3,743,820. 0.08% of the stock is owned by company insiders.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.